Ochnik Michał, Franz Dominika, Sobczyński Maciej, Naporowski Piotr, Banach Mariusz, Orzechowska Beata, Sochocka Marta
Laboratory of Virology, Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology of the Polish Academy of Sciences, 02-093 Warsaw, Poland.
Pharmaceuticals (Basel). 2022 May 17;15(5):619. doi: 10.3390/ph15050619.
Viral and bacterial diseases are among the greatest concerns of humankind since ancient times. Despite tremendous pharmacological progress, there is still a need to search for new drugs that could treat or support the healing processes. A rich source of bioactive compounds with antiviral potency include plants such as black chokeberry and elderberry. The aim of this study was to assess the in vitro antiviral ability of an originally designed double-standardized blend of extracts from (Michx.) Elliot and L. (EAM-ESN) or separated extracts of (EAM) or (ESN) against four human respiratory tract viruses: influenza A virus (A/H1N1), betacoronavirus-1 (HCoV-OC43) belonging to the same β-coronaviruses as the current pandemic SARS-CoV-2, human herpesvirus type 1 (HHV-1), and human adenovirus type 5 (HAdV-5). Antiviral assays (AVAs) were used to evaluate the antiviral activity of the plant extracts in a cell-present environment with extracts tested before, simultaneously, or after viral infection. The virus replication was assessed using the CPE scale or luminescent assay. The EAM-ESN blend strongly inhibited A/H1N1 replication as well as HCoV-OC43, while having a limited effect against HHV-1 and HAdV-5. This activity likely depends mostly on the presence of the extract of . However, the EAM-ESN blend possesses more effective inhibitory activity toward virus replication than its constituent extracts. A post-infection mechanism of action of the EAM-ESN make this blend the most relevant for potential drugs and supportive treatments; thus, the EAM-ESN blend might be considered as a natural remedy in mild, seasonal respiratory viral infections.
自古以来,病毒和细菌疾病一直是人类最为关注的问题之一。尽管药理学取得了巨大进展,但仍需要寻找能够治疗或支持愈合过程的新药。具有抗病毒效力的生物活性化合物的丰富来源包括诸如黑 chokeberry 和接骨木果之类的植物。本研究的目的是评估一种最初设计的由(Michx.)埃利奥特和 L.(EAM - ESN)提取物组成的双标准化混合物,或(EAM)或(ESN)的分离提取物对四种人类呼吸道病毒的体外抗病毒能力:甲型流感病毒(A/H1N1)、与当前大流行的 SARS-CoV-2 属于同一β冠状病毒的β冠状病毒 - 1(HCoV-OC43)、人类 1 型疱疹病毒(HHV-1)和人类 5 型腺病毒(HAdV-5)。抗病毒测定(AVA)用于评估植物提取物在有细胞存在的环境中的抗病毒活性,提取物在病毒感染之前、同时或之后进行测试。使用 CPE 量表或发光测定法评估病毒复制情况。EAM - ESN 混合物强烈抑制 A/H1N1 复制以及 HCoV-OC43,而对 HHV-1 和 HAdV-5 的作用有限。这种活性可能主要取决于提取物的存在。然而,EAM - ESN 混合物对病毒复制的抑制活性比其组成提取物更有效。EAM - ESN 的感染后作用机制使其成为潜在药物和支持性治疗中最相关的;因此,EAM - ESN 混合物可能被视为轻度季节性呼吸道病毒感染的天然疗法。